{
    "clinical_study": {
        "@rank": "55455", 
        "acronym": "VIALE", 
        "arm_group": {
            "arm_group_label": "Warfarin in elderly with comorbidity", 
            "description": "Patients  65 years or older,  candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement"
        }, 
        "biospec_descr": {
            "textblock": "Whole blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to validate the International Warfarin Pharmacogenetics\n      Consortium (IWPC) algorithm in a prospective cohort of elderly people (65 years or older)\n      with heart valves and/or nonvalvular atrial fibrillation (AF) and at least one comorbid\n      condition, and to assess the algorithm's prognostic relevance."
        }, 
        "brief_title": "Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Thrombus Due to Heart Valve Prosthesis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Thrombosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 65 years\n\n          -  Patients who initiate warfarin because of non valvular atrial fibrillation or heart\n             valve replacement\n\n          -  At least one comorbid condition\n\n          -  At least two other drugs regularly assumed over and above warfarin\n\n        Exclusion Criteria:\n\n          -  Presence of systemic coagulopathies\n\n          -  Presence of malignancies needing chemotherapy\n\n          -  Inability or refusal to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "prospective cohort of elderly people (\u226565 years) with nonvalvular atrial fibrillation\n        and/or heart valve replacement, with at least one comorbid condition, presenting for\n        warfarin therapy"
            }
        }, 
        "enrollment": {
            "#text": "1100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069132", 
            "org_study_id": "VIALE", 
            "secondary_id": [
                "FARM9JNT9Y", 
                "2012-002578-30"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Warfarin in elderly with comorbidity", 
            "description": "warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.", 
            "intervention_name": "Warfarin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Warfarin", 
            "International Warfarin Pharmacogenetics Consortium algorithm", 
            "Atrial Fibrillation", 
            "Heart Valve Prosthesis Implantation", 
            "elderly", 
            "comorbidity"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "Second University of Naples"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "University of Naples Federico II"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salerno", 
                        "country": "Italy"
                    }, 
                    "name": "University of Salerno"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Validation of IWPC Pharmacogenetic Algorithm for Estimating the Appropriate Initial Dose of Warfarin in Elderly People (65 or Older) With Heart Valves Prostheses or Non Valvular Atrial Fibrillation and Comorbidity", 
        "overall_contact": {
            "email": "ciro.gallo@unina2.it", 
            "last_name": "Ciro Gallo, MD", 
            "phone": "+39 0815666021"
        }, 
        "overall_contact_backup": {
            "email": "simona.signoriello@unina2.it", 
            "last_name": "Simona Signoriello, Ph.D.", 
            "phone": "+39 0815666021"
        }, 
        "overall_official": [
            {
                "affiliation": "Second University of Naples", 
                "last_name": "Ciro Gallo, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Salerno", 
                "last_name": "Amelia Filippelli, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Second University of Naples", 
                "last_name": "Marisa De Feo, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Federico II University", 
                "last_name": "Nicola Ferrara, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "stable warfarin dosing is defined as the mean daily does required to achieve three or more consecutive International Normalized Ratio (INR) measurements within the individual's target range, at the same daily does.", 
            "measure": "Percentage of patients whose predicted dose of warfarin is within 20% of the actual stable therapeutic dose.", 
            "safety_issue": "No", 
            "time_frame": "up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069132"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Second University of Naples", 
            "investigator_full_name": "Ciro Gallo", 
            "investigator_title": "Professor of Medical Statistics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients for whom the predicted dose is at least 20% higher than the actual dose (overestimation) or at least 20% lower than the actual dose (underestimation).", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "description": "composite endpoint: death for any cause, hospitalization for cardiovascular and cerebrovascular events, major bleeding  or thromboembolism", 
                "measure": "number of cardiovascular and cerebrovascular events", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "major bleeding: (i) fatal bleeding; and/or (ii) symptomatic bleeding in a critical area or organ; and/or (iii) bleeding causing a fall in haemoglobin level of \u22652 g/dL or leading to transfusion of two or more units of blood or red cells.", 
                "measure": "number of patients with major bleeding events", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "thromboembolism is defined as occurrence of cerebral infarction, myocardial infarction, peripheral arterial embolism.", 
                "measure": "number of  thromboembolic event", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "number of cardiovascular and cerebrovascular events", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "number of patient reported episodes of minor bleeding events", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "average maintenance dose per patient", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "time to achievement of stable warfarin dosing from initiation", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "description": "defined as the time of first achieving INR measurement within the individual's target range, providing that INR is also within the target range at the subsequent clinic visit", 
                "measure": "time to therapeutic INR per patient", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "measure": "percentage time in the therapeutic INR range", 
                "safety_issue": "No", 
                "time_frame": "up to 3 months"
            }, 
            {
                "measure": "percentage time in the therapeutic INR range", 
                "safety_issue": "No", 
                "time_frame": "four weeks"
            }
        ], 
        "source": "Second University of Naples", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Federico II University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Salerno", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Second University of Naples", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}